



**Robert Rieben**  
**List of Publications, November 22, 2017**

|                          |       |
|--------------------------|-------|
| H-Index (Research Gate): | 26    |
| Research Gate Score:     | 42.57 |

**Published Items in Each Year**




**Citations in Each Year**



Source: [www.webofknowledge.com](http://www.webofknowledge.com) (Rieben, R [au] NOT Rieben, RN)  
 Complete list of publications, including abstracts and full text:  
[https://www.researchgate.net/profile/Robert\\_Rieben2](https://www.researchgate.net/profile/Robert_Rieben2)

**IF and Ranking**



**Peer Reviewed, Original Papers**

Cumulative IF                    357.81  
 Mean IF and Ranking            3.89            0.73

|   |                     |
|---|---------------------|
| <p>92. Gygax E, Kaeser H, Stalder M, Carrel T, Gahl B, Despont A, <b>Rieben R</b>, Erdoes G. Surgical Aortic valve replacement using minimal invasive extracorporeal circulation: Non-inferiority to conventional extracorporeal circulation. <i>Artificial Organs</i> 2017, in press</p> | <p>2.40    0.65</p> |
| <p>91. Zhang S, Shaw J, Banz Y, Bongoni AK, Taddeo A, Spirig R, Nolte MW, Cowan PJ, <b>Rieben R</b>. Effects of C1 inhibitor on endothelial cell activation in a rat hind limb ischemia/reperfusion injury model. <i>J Vasc Surg</i> 2017, in press</p>                                   | <p>3.54    0.85</p> |

| No. | Reference  | IF   | Rank |
|-----|--|------|------|
| 90. | Puga Yung G, Bongoni A, Pradier A, Madelon N, Papaserafeim M, Sfriso R, Ayares D, Wolf E, Klymiuk N, Bähr A, Constantinescu M, Vögelin E, Kiermeir D, Jenni HJ, <b>Rieben R</b> , Seebach JD. Release of pig leukocytes and reduced human NK cell recruitment during ex vivo perfusion of HLA-E/human CD46 double-transgenic pig limbs with human blood. Xenotransplantation 2017, in press. | 3.96 | 0.84 |
| 89. | Sfriso R, Bongoni A, Banz Y, Klymiuk N, Wolf E, <b>Rieben R</b> . Assessment of the anticoagulant and anti-inflammatory properties of endothelial cells using 3D cell culture and non-anticoagulated whole blood. J Vis Exp 2017, 127:e56227. DOI 10.3791/56227.   | 1.23 | 0.59 |
| 88. | Olariu R, Denoyelle J, Leclère FM, Dzhonova DV, Gajanayake T, Banz Y, Hayoz M, Constantinescu M, <b>Rieben R</b> , Vögelin E, Taddeo A. Intra-graft injection of tacrolimus promotes survival of vascularized composite allotransplantation. J Surg Res 2017, 218:49-57. DOI 10.1016/j.jss.2017.05.046.  | 2.19 | 0.61 |
| 87. | Duisit, J, Maistriaux L, Taddeo A, Orlando G, Joris V, Coche E, Behets C, Lerut J, Dessy C, Cossu G, Vögelin E, <b>Rieben R</b> , Gianello P, Lengelé B. Bioengineering a human face graft. The matrix of identity. Ann Surg 2017 in press. DOI 10.1097/SLA.0000000000002396   | 8.98 | 1.00 |
| 86. | Bongoni AK, Salvaris E, Nordling S, Klymiuk N, Wolf E, Ayares DL, <b>Rieben R</b> , Magnusson PU, Cowan PJ. Surface modification of pig endothelial cells with a branched heparin conjugate improves their compatibility with human blood. Scientific Reports 2017, 7:4450. DOI 10.1038/s41598-017-04898-w.  | 4.26 | 0.86 |
| 85. | Abdelhafez MM, Shaw J, Sutter D, Schnider J, Banz Y, Jenni HJ, Voegelin E, Constantinescu MA, <b>Rieben R</b> . Effect of C1-INH on ischemia/reperfusion injury in a porcine limb ex vivo perfusion model. Molecular Immunology 2017, 88:11-6124. DOI 10.1016/j.molimm.2017.06.021.  | 3.24 | 0.61 |
| 84. | Pischke SE, Gustavsen A, Orrem HL, Egge KH, Courivaud F, Fontenelle H, Despont A, Bongoni AK, <b>Rieben R</b> , Tønnessen TI, Nunn MA, Scott H, Skultad H, Barrat-Due A, Mollnes TE. Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function. Basic Research in Cardiology 2017, 112(3):20. DOI 10.1007/s00395-017-0610-9.           | 5.31 | 0.83 |
| 83. | Zhang S, Wotzkow C, Bongoni AK, Shaw-boden J, Siegrist M, Taddeo A, Blank F, Hofstetter W, <b>Rieben R</b> . Role of the plasma cascade systems in ischemia/reperfusion injury of bone. Bone 2017, 97:278-286.   | 4.14 | 0.77 |
| 82. | Kamat P, Vandenberghe S, Christen S, Bongoni AK, Meier B, <b>Rieben R*</b> , Khattab A. Dexrazoxane shows no protective effect in the acute phase of reperfusion during myocardial infarction in pigs. PLOS ONE 2016, 11(12):e0168541.<br>*corresponding author  | 2.81 | 0.78 |

| No. | Reference   | IF   | Rank |
|-----|---|------|------|
| 81. | Zandi S, Tappeiner C, Pfister IB, Despont A, <b>Rieben R</b> , Garweg JG. Vitreal cytokine profile differences between eyes with epiretinal membranes or macular holes. <i>Invest Ophthalmol Vis Sci</i> 2016, 57:6320-6326.  | 3.30 | 0.83 |
| 80. | Bongoni AK, Klymiuk N, Wolf E, Ayares D, <b>Rieben R</b> , Cowan PJ. Transgenic expression of human thrombomodulin inhibits HMGB1-induced porcine aortic endothelial cell activation. <i>Transplantation</i> 2016, 100:1871-1879.   | 3.68 | 0.86 |
| 79. | Spirig A, Juon B, Banz Y, <b>Rieben R</b> , Vögelin E. Correlation between sonographic and in vivo measurement of A1 pulleys in trigger fingers. <i>Ultrasound in Medicine and Biology</i> 2016, 42(7):1482-1490.   | 2.49 | 0.84 |
| 78. | Zuccarella-Hackl C, von Känel R, Thomas L, Kuebler P, Schmid JP, Mattle HP, Mono ML, <b>Rieben R</b> , Wiest R, Wirtz, PH. Higher macrophage superoxide anion production in coronary artery disease (CAD) patients with Type D personality. <i>Psychoneuroendocrinology</i> 2016, 68:186-193.   | 4.79 | 0.91 |
| 77. | Zhang S, Duehrkop C, Plock J, <b>Rieben R</b> . Inhalation anesthesia of rats: Influence of the fraction of inspired oxygen on limb ischemia/reperfusion injury. <i>Laboratory Animals</i> 2015, 50(3):185-197.   | 1.53 | 0.76 |
| 76. | Banz Y, Item GM, Vogt A, <b>Rieben R</b> , Candinas D, Beldi, G. Endothelial- and Platelet-derived Microparticles are generated during Liver Resection in Humans. <i>Journal of Investigative Surgery</i> 2015, 29(1):20-31.  | 1.53 | 0.43 |
| 75. | Bongoni AK, Kiermeir D, Schnider J, Jenni HJ, Garimella PS, Bähr A, Klymiuk N, Wolf E, Ayares D, Voegelin E, Constantinescu MA, Seebach JD, <b>Rieben R</b> . Transgenic Expression of Human CD46 on Porcine Endothelium: Effect on Coagulation and Fibrinolytic Cascades During Ex Vivo Human-to-Pig Limb Xenoperfusions. <i>Transplantation</i> 2015, 99(10):2061-2069. | 3.68 | 0.86 |
| 74. | Egge KH, Thorgersen EB, Pischke SE, Lindstad JK, Anne Pharo A, Bongoni AK, <b>Rieben R</b> , Nunn MA, Barratt-Due A, Mollnes TE. Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. <i>Immunobiology</i> 2015, 220(8):999-1005.  | 2.72 | 0.42 |
| 73. | Ahrens HE, Petersen B, Herrmann D, Lucas-Hahn A, Hassel P, Ziegler M, Kues WA, Baulain U, Baars W, Schwinzer R, Denner J, Rataj D, Werwitzke S, Tiede A, Bongoni AK, Garimella PS, Despont A, <b>Rieben R</b> , Niemann H. siRNA Mediated Knockdown of Tissue Factor Expression in Pigs for Xenotransplantation. <i>Am J Transplant</i> 2015, 15(5):1407-1414.            | 6.17 | 0.98 |
| 72. | Bongoni AK, Kiermeir D, Denoyelle J, Jenni H, Burlak C, Seebach JD, Voegelin E, Constantinescu MA, <b>Rieben R</b> . Porcine extrahepatic vascular endothelial ASRG1 mediates platelet phagocytosis in vitro and in human-to-pig ex vivo xenoperfusion. <i>Transplantation</i> 2015, 99(4):693-701.   | 3.68 | 0.86 |

| No. | Reference  | IF    | Rank |
|-----|--|-------|------|
| 71. | Gajanayake T, Olariu R, Leclère FM, Dhayani A, Yang Z, Bongoni AK, Banz Y, Constantinescu MA, Karp JM*, Vemula PK*, <b>Rieben R*</b> , Vögelin E. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. <i>Sci Transl Med</i> 2014, 6:249ra110.<br>*co-corresponding authors  | 16.80 | 0.99 |
| 70. | Bongoni AK, Kiermeir D, Jenni H, Bähr A, Ayares D, Klymiuk N, Wolf E, Voegelin E, Constantinescu MA, Seebach JD, <b>Rieben R</b> . Complement dependent early immunological responses during ex vivo xenoperfusion of hCD46/HLA-E double transgenic pig forelimbs with human blood. <i>Xenotransplantation</i> 2014, 21(3):230-243.  | 3.96  | 0.84 |
| 69. | Dührkop C, <b>Rieben R</b> . Refinement of tourniquet-induced peripheral ischemia/reperfusion injury in rats: Comparison of 2h vs. 24h reperfusion. <i>Laboratory Animals</i> 2014, 48(2):143-154.   | 1.53  | 0.76 |
| 68. | Dührkop C, Denoyelle J, Shaw S, <b>Rieben R</b> . Use of dextran sulfate in tourniquet-induced skeletal muscle reperfusion injury. <i>J Surg Res</i> 2014, 187(1):150-161.   | 2.19  | 0.61 |
| 67. | Wünsch A, Bähr A, Bongoni AK, Kemter E, Blutke A, Baars W, Haertle S, Zakhartchenko V, Kurome M, Kessler B, Faber C, Reichart B, Wanke R, Schwinzer R, Nagashima H, <b>Rieben R</b> , Ayares D, Wolf E, Klymiuk N. Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs. <i>Transplantation</i> 2014, 97(2):138-147. | 3.68  | 0.86 |
| 66. | Schweizer DF, Schweizer R, Zhang S, Kamat P, Contaldo C, <b>Rieben R</b> , Eberli D, Giovanoli P, Erni D, Plock JA. Botulinum toxin A and B raise blood flow and increase survival of critically ischemic skin flaps. <i>J Surg Res</i> 2013, 184:1205–1213.   | 2.19  | 0.61 |
| 65. | Bongoni AK, Kiermeir D, Jenni H, Wünsch A, Bähr A, Ayares D, Seebach JD, Wolf E, Klymiuk N, Constantinescu MA, Vögelin E, <b>Rieben R</b> . Activation of the Lectin Pathway of Complement in Pig-to-Human Xenotransplantation Models. <i>Transplantation</i> 2013, 96(9):791-799.   | 3.68  | 0.86 |
| 64. | Khatab AA, Stieger S, Kamat PJ, Vandenberghe S, Bongoni A, Stone GW, Seiler C, Meier B, Hess OM, <b>Rieben R</b> . Effect of pressure-controlled intermittent coronary sinus occlusion (PICSO) on myocardial ischaemia and reperfusion in a closed-chest porcine model. <i>EuroIntervention</i> 2013, 9:398–406.   | 5.17  | 0.82 |
| 63. | Barratt-Due A, Thorgersen EB, Egge K, Pischke S, Sokolov A, Hellerud BC, Lindstad JK, Pharo A, Bongoni AK, <b>Rieben R</b> , Nunn M, Scott H, Mollnes TE. Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity, and hemodynamic changes in porcine sepsis. <i>J Immunol</i> 2013, 191:819–827.  | 4.86  | 0.79 |
| 62. | Bongoni AK, Lanz J, <b>Rieben R</b> , Banz Y. Development of a bead-based multiplex assay for the simultaneous detection of porcine inflammation markers using xMAP technology. <i>Cytometry A</i> 2013, 83:636–647.   | 3.22  | 0.64 |

| No. | Reference   | IF   | Rank |
|-----|---|------|------|
| 61. | Ruder TD, Ebert LC, Khattab AA, <b>Rieben R</b> , Thali MJ, Kamat P. Edema is a sign of early acute myocardial infarction on post-mortem magnetic resonance imaging. <i>Forensic Sci Med Pathol</i> 2013, 9(4):501-505.   | 1.84 | 0.67 |
| 60. | Müller S, Constantinescu MA, Kiermeir DM, Gajanayake T, Bongoni AK, Vollbach FH, Meoli M, Plock J, Jenni H, Banic A, <b>Rieben R*</b> , Vögelin E. Ischemia/reperfusion injury of porcine limbs after extracorporeal perfusion. <i>J Surg Res</i> 2013, 181:170–182.<br>*corresponding author                   | 2.19 | 0.61 |
| 59. | Leclère FMP, Lewbart GA, <b>Rieben R</b> , Vögelin E. Microsurgery and liver research: <i>Lumbricus terrestris</i> , a reliable animal model for training? <i>Clin Res Hepatol Gastroenterol</i> 2013, 37:166–170.  | 2.32 | 0.34 |
| 58. | Duehrkop C, Banz Y, Spirig R, Miescher S, Nolte MW, Spycher M, Smith RAG, Sacks SH, <b>Rieben R</b> . C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage. <i>PLoS ONE</i> 2013, 8:e72059.   | 2.81 | 0.78 |
| 57. | Spirig R, Schaub A, Kropf A, Miescher S, Spycher MO, <b>Rieben R</b> . Reconstituted high-density lipoprotein modulates activation of human leukocytes. <i>PLoS One</i> 2013, 8(8), e71235.   | 2.81 | 0.78 |
| 56. | Kamat P, Juon B, Jossen B, Gajanayake T, <b>Rieben R*</b> , Vögelin E. Assessment of endothelium and inflammatory response at the onset of reperfusion injury in hand surgery. <i>J Inflamm (Lond)</i> 2012, 9:18-28.<br>*corresponding author  | 2.50 | 0.36 |
| 55. | Veres-Nyeki KO, <b>Rieben R</b> , Spadavecchia C, Bergadano A. Pancuronium dose refinement in experimental pigs used in cardiovascular research. <i>Vet Anaest Analg</i> 2012, 39(5):529-532.   | 1.77 | 0.84 |
| 54. | Banz Y, Hess OM, Meier P, Korchagina EY, Gordeeva EA, Robson SC, Gajanayake T, Csizmadia E, Mettler D, Haeberli A, Bovin NV, <b>Rieben R</b> . Evaluation of multimeric tyrosine-O-sulfate as a cytoprotectant in an in vivo model of acute myocardial infarction in pigs. <i>Cardiology</i> 2012, 121:59-70.   | 1.74 | 0.32 |
| 53. | Jenni H, Rheinberger J, Czerny M, Gygax E, <b>Rieben R</b> , Krähenbühl E, Carrel T, Stalder M. Autotransfusion system or integrated automatic suction device in minimized extracorporeal circulation: influence on coagulation and inflammatory response. <i>Eur J Cardiothorac Surg</i> 2011, 39(5): e139-43. | 3.76 | 0.88 |
| 52. | Pochechueva T, Chinarev A, Spengler M, Korchagina E, Heinzelmann-Schwarz V, Bovin N, <b>Rieben R</b> . Multiplex suspension array for human anti-carbohydrate antibody profiling. <i>Analyst</i> 2011, 136:560-569.   | 3.89 | 0.86 |
| 51. | Spirig R, Djafarzadeh S, Regueira T, Shaw SG, von Garnier C, Takala J, Jakob SM, <b>Rieben R</b> , Lepper PM. Effects of TLR agonists on the hypoxia-regulated transcription factor HIF-1alpha and dendritic cell maturation under normoxic conditions. <i>PLoS One</i> 2010 5(6):e0010983.                     | 2.81 | 0.78 |

| No. | Reference  | IF   | Rank |
|-----|--|------|------|
| 50. | Millard AL, Spirig R, Mueller NJ, Seebach JD, <b>Rieben R</b> . Inhibition of direct and indirect TLR-mediated activation of human NK cells by low molecular weight dextran sulfate. <i>Mol Immunol</i> 2010 47(14):2349-2358.   | 3.24 | 0.61 |
| 49. | Constantinescu MA, Knall E, Xu X, Kiermeir DM, Jenni HJ, Gyax E, <b>Rieben R</b> , Banic A, Vögelin E. Preservation of amputated extremities by extracorporeal blood perfusion; a feasibility study in a porcine model. <i>J Surg Res</i> 2011, 171:291-299.   | 2.19 | 0.61 |
| 48. | Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, Hoeffler L, <b>Rieben R</b> . In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations. <i>Vox Sang</i> 2009 97(4):348-354.   | 2.19 | 0.43 |
| 47. | Spirig R, Potapova I, Shaw-Boden J, Tsui J, <b>Rieben R</b> , Shaw SG. TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. <i>Mol Immunol</i> 2009 46(15):3178-3182.   | 3.24 | 0.61 |
| 46. | Banz Y, Gajanayake T, Matozan K, Yang Z, <b>Rieben R</b> . Dextran sulfate modulates MAP kinase signaling and reduces endothelial injury in a rat aortic clamping model. <i>J Vasc Surg</i> 2009 50(1):161-170.  | 3.54 | 0.85 |
| 45. | Gajanayake T, Sawitzki B, Matozan K, Korchagina EY, Lehmann M, Volk HD, <b>Rieben R</b> . Dextran Sulfate Facilitates Anti-CD4 mAb-Induced Long-Term Rat Cardiac Allograft Survival After Prolonged Cold Ischemia. <i>Am J Transplant</i> 2008 8(6):1151-1162.                                       | 6.17 | 0.98 |
| 44. | Spirig R, van Kooten C, Obregon C, Nicod L, Daha MR, <b>Rieben R</b> . The Complement Inhibitor Low Molecular Weight Dextran Sulfate Prevents TLR4-Induced Phenotypic and Functional Maturation of Human Dendritic Cells. <i>J Immunol</i> 2008 181(2):878-890.                                      | 4.86 | 0.79 |
| 43. | Banz Y, <b>Rieben R*</b> , Zobrist C, Meier P, Shaw S, Lanz J, Carrel T, Berdat P. Addition of dextran sulfate to blood cardioplegia attenuates reperfusion injury in a porcine model of cardiopulmonary bypass. <i>Eur J Cardiothorac Surg</i> 2008 34(3):653-660.<br>*corresponding author         | 3.76 | 0.88 |
| 42. | Stüssi G, Müller RJ, Passweg J, Schanz U, <b>Rieben R</b> , Seebach JD. ABO blood group incompatible haematopoietic stem cell transplantation and xenograft rejection. <i>Swiss Med Wkly</i> 2007 137(Suppl. 155):101S-108S.   | 1.65 | 0.57 |
| 41. | Obukhova P, <b>Rieben R</b> , Bovin NV. Normal human serum contains high levels of anti Gal $\alpha$ 1-4GlcNAc antibodies. <i>Xenotransplantation</i> 2007 14(6): 627-635.   | 3.96 | 0.84 |
| 40. | Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P, Haeberli A, Shaw S, Smith RA, <b>Rieben R</b> . Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. <i>Cardiovascular Research</i> 2007 76(3):482-493. | 5.88 | 0.86 |

| No. | Reference   | IF    | Rank |
|-----|---|-------|------|
| 39. | Tanner H, Mohacsi P, Fuller-Bicer GA, <b>Rieben R</b> , Meier B, Hess O, Hullin R. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. <i>J Heart Lung Transplant</i> 2007 26(6):622-629.   | 7.11  | 1.00 |
| 38. | Baumann BC, Stüssi G, Huggel K, Hawley RJ, <b>Rieben R</b> , and Seebach JD. Reactivity of human natural antibodies to endothelial cells from Gal alpha(1,3) Gal-deficient pigs. <i>Transplantation</i> 2007 83(2):193-201.   | 3.68  | 0.86 |
| 37. | Banz Y, Hess OM, Robson SC, Mettler D, Meier P, Haeberli A, Csizmadia E, Korchagina EY, Bovin NV, <b>Rieben R</b> . Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischemia/reperfusion injury. <i>Eur Heart J</i> 2005 26(21):2334-2343.  | 19.65 | 0.99 |
| 36. | Stüssi G, Huggel K, Lutz HU, Schanz U, <b>Rieben R</b> . Seebach JD. Isotype-specific detection of ABO blood group antibodies using a novel, flow cytometric method. <i>Br J Haematol</i> 2005 130(6):954-963.  | 5.67  | 0.87 |
| 35. | Banz Y, Cung T, Korchagina EY, Bovin NV, Haeberli Y, <b>Rieben R</b> . Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood. <i>Xenotransplantation</i> 2005 12(6):434-443.   | 3.96  | 0.84 |
| 34. | Baumann BC, Forte P, Hawley RJ, <b>Rieben R</b> , Schneider MKJ, Seebach JD. Lack of Gal $\alpha$ (1-3)Gal expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. <i>J Immunol</i> 2004 172(10):6460-6467.  | 4.86  | 0.79 |
| 33. | Laumonier T, Walpen AJ, Matozan KM, Korchagina EY, Bovin NV, Haeberli A, Mohacsi PJ, <b>Rieben R</b> . Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models. <i>Xenotransplantation</i> 2004 11(3):262-268.  | 3.96  | 0.84 |
| 32. | Laumonier T, Mohacsi PJ, Matozan KM, Banz Y, Haeberli A, Korchagina EY, Bovin NV, Vanhove B, <b>Rieben R</b> . Endothelial Cell protection by dextran sulfate: A novel strategy to prevent acute vascular rejection in xenotransplantation. <i>Amer J Transpl</i> 2004 4(2):181-187.  | 6.17  | 0.98 |
| 31. | Walpen A, Laumonier T, Aebi C, Mohacsi PJ, <b>Rieben R</b> . Immunoglobulin M-enriched intravenous immunoglobulin inhibits classical pathway complement activation, but not bactericidal activity of human serum. <i>Xenotransplantation</i> 2004 11(2):141-148.  | 3.96  | 0.84 |
| 30. | Laumonier T, Walpen AJ, Maurus CF, Mohacsi PJ, Matozan KM, Korchagina EY, Bovin NV, Vanhove B, Seebach JD, <b>Rieben R</b> . Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells. <i>Transplantation</i> 2003 76(5):838-843. | 3.68  | 0.86 |
| 29. | Pochechueva TV, Ushakova NA, Preobrazhenskaya ME, Nifant'ev NE, Tsvetkov YE, Sablina MA, Tuzikov AB, Bird MI, <b>Rieben R</b> . Bovin NV. P-selectin blocking potency of multimeric tyrosine sulfates in vitro and in vivo. <i>Bioorg Med Chem Lett</i> 2003 13(10):1709-1712.  | 2.93  | 0.75 |

| No. | Reference   | IF   | Rank |
|-----|---|------|------|
| 28. | Tsvetkov DE, Cheshev, PE, Tuzikov AB, Chinarev AA, Pazynina GV, Sablina MA, Gambaryan AS, Bovin NV, <b>Rieben R</b> , Shashkov AS, Nifant'ev NE. Neoglycoconjugates based on dendrimers poly(aminoamides). Russian Journal of Bioorganic Chemistry 2002 28(6):470-486.  | 0.69 | 0.19 |
| 27. | Pierson RN 3rd, Loyd JE, Goodwin A, Majors D, Dummer JS, Mohacsi P, Wheeler A, Bovin N, Miller GG, Olson S, Johnson J, <b>Rieben R</b> , Azimzadeh A. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoabsorption, complement inhibition, and immunomodulatory therapy. Transplantation 2002 74(1):79-84. | 3.68 | 0.86 |
| 26. | Roos A, <b>Rieben R</b> , Faber-Krol MC, Daha MR. IgM-enriched human intravenous immunoglobulin strongly inhibits complement-dependent porcine cell cytotoxicity mediated by human xenoreactive antibodies. Xenotransplantation 2003 10(6):596-605.   | 3.96 | 0.84 |
| 25. | Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen H-U, Zürcher-Zenklusen R, <b>Rieben R</b> , Devay J, Hack CE, Lämmle B, Wuillemin WA. C1-inhibitor in patients with severe sepsis or septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002 30(8):1722-1728.   | 7.05 | 0.91 |
| 24. | Walpen AJ, Mohacsi PJ, Frey C, Roos A, Daha MR, <b>Rieben R</b> . Activation of complement pathways in xenotransplantation: an in vitro study. Transplant Immunol 2002 9(2-4):271-280.  | 1.78 | 0.36 |
| 23. | Mohacsi P, <b>Rieben R</b> , Sigurdsson G, Tschanz HU, Schaffner T, Nydegger UE, Carrel T. Successful management of a B-type cardiac allograft into an O-type man with 31/2 year clinical follow-up. Transplantation 2001 72(7):1328-1330.  | 3.68 | 0.86 |
| 22. | Basker M, Alwayn IPJ, Buhler L, Harper D, Abraham S, Kruger Gray H, Awwad M, Down J, <b>Rieben R</b> , White-Scharf ME, Sachs DH, Thall A, Cooper DKC. Clearance of mobilized porcine peripheral blood progenitor cells is delayed by depletion of the phagocytic reticuloendothelial system in baboons. Transplantation 2001 72(7):1278-1285.  | 3.68 | 0.86 |
| 21. | Gerber B, Tinguely C, Bovin NV, <b>Rieben R</b> , Nydegger UE. Differences between synthetic oligosaccharide immunoabsorbents in depletion capacity for xenoreactive anti-Gal $\alpha$ 1-3Gal antibodies from human serum. Xenotransplantation 2001 8(2):106-114.   | 3.96 | 0.84 |
| 20. | Fiorante P, Banz Y, Mohacsi PJ, Kappeler A, Wuillemin WA, Macchiarini P, Roos A, Daha MR, Schaffner T, Haeberli A, Mazmanian GM, <b>Rieben R</b> . Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models. Xenotransplantation 2001 8(1):24-35.         | 3.96 | 0.84 |
| 19. | <b>Rieben R</b> , Bovin NV, Korchagina EY, Oriol R, Nifant'ev NE, Tsvetkov DE, Daha MR, Mohacsi PJ, Joziassse DH. Xenotransplantation: in vitro analysis of synthetic $\alpha$ -galactosyl inhibitors of human anti-Gal $\alpha$ 1-3Gal IgM and IgG antibodies. Glycobiology 2000 10(2):141-148.  | 3.11 | 0.57 |




| No. | Reference   | IF    | Rank |
|-----|---|-------|------|
| 18. | Buonomano R, Tinguely C, <b>Rieben R</b> , Mohacsi PJ, Nydegger UE. Quantitation and characterization of anti-Gal $\alpha$ 1-3Gal antibodies in sera of 200 healthy persons. <i>Xenotransplantation</i> 1999 6(3):173-180.  | 3.96  | 0.84 |
| 17. | Tsvetkov DE, Cheshev PE, Tuzikov AB, Pzynina GV, <b>Rieben R</b> , Bovin NV, Nifant'ev NE. Synthesis of neoglycoconjugate dendrimers. <i>Mendeleev Commun</i> 1999:47-50.   | 1.74  | 0.47 |
| 16. | <b>Rieben R</b> , Roos A, Muizert Y, Tinguely C, Gerritsen AF, Daha MR. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. <i>Blood</i> 1999 93(3):942-951.   | 13.16 | 0.99 |
| 15. | Macchiarini P, Oriol R, Azimzadeh A, de Montpreville V, <b>Rieben R</b> , Bovin N, Dartevelle P. Evidence of human non-alpha Gal antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. <i>J Thorac Cardiovasc Surg</i> 1998 116(5):831-843.  | 4.45  | 0.94 |
| 14. | Uetz-von Allmen E, Sturzenegger M, <b>Rieben R</b> , Rihs F, Frauenfelder A, Nydegger UE. Anti-ganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls. <i>Eur Neurol</i> 1998 39(2):103-110.  | 1.70  | 0.29 |
| 13. | Macchiarini P, Mazmanian GM, Oriol R, de Montpreville V, Dulmet E, Fattal S, Libert JM, Dubin S, Nochy D, <b>Rieben R</b> , Dartevelle P. Ex-vivo lung model of pig-to-human hyperacute xenograft rejection. <i>J Thorac Cardiovasc Surg</i> 1997 114(3):315-325.   | 4.45  | 0.94 |
| 12. | <b>Rieben R</b> , Korchagina EY, Bovin NV, Daha MR. Specificity of monoclonal antibodies against ABH- and related structures tested by ELISA with synthetic glycoconjugates. <i>Transf Clin Biol</i> 1997 1:47-54.  | 0.74  | 0.07 |
| 11. | Friedli F, <b>Rieben R</b> , Wegmüller E, Moerenhout M, Nydegger UE. Normal levels of allo- but increased levels of potentially autoreactive antibodies against ABO histo-blood group antigens in AIDS patients. <i>Clin Immunol Immunopathol</i> 1996 80(1):96-100.  | 3.99  | 0.72 |
| 10. | <b>Rieben R</b> , Frauenfelder A, Nydegger UE. Spectrotype analysis of human ABO antibodies: evidence for different clonal heterogeneity of IgM, IgG, and IgA antibody populations. <i>Vox Sang</i> 1996; 70:104-111.   | 2.19  | 0.43 |
| 9.  | <b>Rieben R</b> , von Allmen E, Korchagina EY, Nydegger UE, Neethling, FA, Kujundzic M, Koren E, Bovin NV, Cooper DKC. Detection, immunoabsorption, and inhibition of cytotoxic activity of anti-alpha Gal antibodies using newly developed substances with synthetic Gal alpha1-3 Gal disaccharide epitopes. <i>Xenotransplantation</i> 1995;2:98-106. | 3.96  | 0.84 |
| 8.  | <b>Rieben R</b> , Korchagina EY, von Allmen E, Kremer Hovinga J, Lämmle B, Jungi T, Bovin NV, Nydegger UE. In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. <i>Transplantation</i> 1995;60(5):425-430.  | 3.68  | 0.86 |

| No. | Reference   | IF   | Rank |
|-----|---|------|------|
| 7.  | von Allmen E, <b>Rieben R</b> , Nydegger UE. Development of a C1q-ABO-ELISA to measure C1 binding by human anti-A alloantibodies. J Immunol Methods 1994;171(1):85-92.  | 2.10 | 0.39 |
| 6.  | Auf der Maur C, Hodel M, Nydegger UE, <b>Rieben R</b> . Age-dependency of ABO histo-blood group antibodies - reexamination of an old dogma. Transfusion 1993;33(11):915-918.  | 3.39 | 0.67 |
| 5.  | <b>Rieben R</b> , Tucci M, Nydegger UE, Zubler RH. Self tolerance to human-A and human-B histo-blood group antigens exists at the B-cell level and cannot be broken by potent polyclonal B-cell activation in vitro. Eur J Immunol 1992;22(10):2713-2717. | 4.23 | 0.74 |
| 4.  | <b>Rieben R</b> , Frauenfelder A, Nydegger UE. Naturally occurring ABO antibodies - long-term stable, individually distinct anti-A IgG spectrotypes. Eur J Immunol 1992;22(8):2129-2133.  | 4.23 | 0.74 |
| 3.  | Hasler CR, <b>Rieben R</b> , Buchs JP, Nydegger UE. Comparison between the levels of anti-A/B IgM/G antibodies in paired mother/child serum samples. Transfus Sci 1992;13(1):113-118.   | 1.30 | 0.17 |
| 2.  | <b>Rieben R</b> , Buchs JP, Flückiger E, Nydegger UE. Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categories. Transfusion 1991;31(7):607-15.               | 3.23 | 0.68 |
| 1.  | <b>Rieben R</b> , Blaser K. Quantification of IgG and IgG4 antibodies to bee venom phospholipase A2 by competitive inhibition in ELISA. J Immunol Methods 1989;119(1):1-8.  | 2.10 | 0.39 |

## Reviews, Book Sections, Case Reports, Letters, Editorials

Cumulative IF                    52.53  
 Mean IF and Ranking         3.50  
    0.61



| No. | Reference   | IF   | Rank |
|-----|---|------|------|
| 25. | Puga Yung G, <b>Rieben R</b> , Bühler L, Schuurman, HJ, Seebach JD. Xenotransplantation: where do we stand in 2016? Swiss Medical Weekly 2017, 147:w14403.  | 1.65 | 0.57 |
| 24. | Cowan P, <b>Rieben R</b> . Modifying the Glycome in Pigs for Xenotransplantation. Transplantation 2016, 100(3):485-486.   | 3.68 | 0.86 |
| 23. | Ahrens HE, Petersen B, Herrmann D, Schwinzer R, Rataj D, Tiede A, Winkler M, Ramakers W, Bongoni A, <b>Rieben R</b> , Niemann H. Experimental approaches towards overcoming the acute vascular rejection during pig-to-primate xenotransplantation. Züchtungskunde 2016, 88(1):32-51. | —    | —    |
| 22. | Duehrkop C, <b>Rieben R</b> . Ischemia/reperfusion injury: Effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition. Biochem Pharmacol 2014, 88(1):12–22.  | 4.58 | 0.89 |
| 21. | Banz Y, <b>Rieben R</b> . Role of complement and perspectives for intervention in ischemia-reperfusion damage. Annals of Medicine 2012, 44(3):205-217.  | 3.72 | 0.87 |
| 20. | Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, <b>Rieben R</b> . Intravenous immunoglobulins – understanding properties and mechanisms. Clin Exp Immunol 2009 158(Suppl 1):2-13.   | 3.41 | 0.60 |
| 19. | Spirig R, Gajanayake T, Korsgren O, Nilsson B, <b>Rieben R</b> . Low molecular weight dextran sulfate as complement inhibitor and cytoprotectant in solid organ and islet transplantation. Mol Immunol 2008 45(16):4084-4094.   | 3.24 | 0.61 |
| 18. | Banz Y, <b>Rieben R</b> . Exploring natural anticoagulation by endothelial cells: A novel in vitro model. ALTEX 2007 24(special issue):9-11.  | 3.83 | 0.78 |
| 17. | Banz Y, <b>Rieben R</b> . Exploring the natural anticoagulation by endothelial cells: A novel in vitro model. 3R-Info-Bulletin no. 34, January 2007.  | —    | —    |

| No. | Reference   | IF    | Rank |
|-----|---|-------|------|
| 16. | Stüssi G, Müller RJ, Passweg J, Schanz U, <b>Rieben R</b> , Seebach JD. ABO blood group incompatible hematopoietic stem cell transplantation and xenograft rejection. <i>Swiss Med Wkly</i> 2007 137(1-2):13-20.  | 1.65  | 0.57 |
| 15. | Banz Y, <b>Rieben R</b> . Endothelial cell protection in xenotransplantation: looking after a key player in rejection. <i>Xenotransplantation</i> 2006 13(1):19-30.   | 3.96  | 0.84 |
| 14. | Nydegger UE, <b>Rieben R</b> . ABO-, nicht aber HLA-Gewebemerkmale schaffen es in die Tagespresse. <i>Schweiz Med Forum</i> 2005 5:1283–1284.   | —     | —    |
| 13. | Nydegger UE, Tevaearai H, Berdat P, <b>Rieben R</b> , Carrel T, Mohacsi P, Flegel WA. Histo-blood group antigens as allo- and autoantigens. <i>Ann N Y Acad Sci</i> 2005 1050:40-51.  | 4.71  | 0.89 |
| 12. | <b>Rieben R</b> , Seebach JD. Xenograft rejection: IgG(1), complement and NK cells team up to activate and destroy the endothelium. <i>Trends Immunol</i> 2005 26(1):2-5.   | 13.29 | 0.97 |
| 11. | Nydegger UE, <b>Rieben R</b> , Carrel T, Mohacsi P. Solid organ transplantation across the ABO histo-blood group barrier: a case report. <i>Transplant Proc.</i> 2004 36:1554-7.  | 0.91  | 0.20 |
| 10. | Nydegger UE, <b>Rieben R</b> , Mohacsi PJ. Current precision of immunological extracorporeal plasma treatment. <i>Transfus Apheresis Sci</i> 2001 24(1):39-47.  | 1.30  | 0.17 |
| 9.  | <b>Rieben R</b> . Xenotransplantation – Beteiligungserfahrung Biotech, 4. EU-Forschungsrahmenprogramm. <i>Euroscope-CH</i> 2000 79:10-11.   | —     | —    |
| 8.  | <b>Rieben R</b> . Xenotransplantationsforschung in der Schweiz - Plädoyer für eine interdisziplinäre Zusammenarbeit. In: <i>Potential and risk of xenotransplantation / Potential und Risiken der Xenotransplantation - Was Experten dazu meinen</i> (Seebach JD, Candinas D, Largiader F, eds.) Luce Verlag, Murten 2000; pp. 158–163. | —     | —    |
| 7.  | Nydegger UE, <b>Rieben R</b> , Lämmle B. Biocompatibility in transfusion medicine. <i>Transfusion Sci</i> 1996 17(4): 10-15.  | 1.30  | 0.17 |
| 6.  | Nydegger UE, <b>Rieben R</b> . Combined use of plasma exchange and intravenous immunoglobulins. <i>Ann Med Int (Paris)</i> 1994;145(5):287-292.   | —     | —    |
| 5.  | Zubler RH, Tucci A, <b>Rieben R</b> , Matthes T, Nydegger UE. Quantification of autoreactive lymphocytes in health and disease. In: <i>Autoimmunity: Physiology and Disease</i> (Cautinho A and Kazatchkine MD, eds.) Wiley-Liss Inc., New York 1994; pp. 173-190.  | —     | —    |
| 4.  | Nydegger UE, <b>Rieben R</b> , Kazatchkine MD. Intravenöse Immunglobulintherapie als Beeinflussungsmöglichkeit von autoimmunen Prozessen. In: <i>Infektionen und Autoimmunerkrankungen II: Therapie mit Immunglobulinen und deren Derivaten</i> (Salama A, Kurrle R eds.) Universitätsverlag Jena 1993; pp 15-27.                       | —     | —    |

| No. | Reference  | IF   | Rank |
|-----|--|------|------|
| 3.  | Nydegger U, <b>Rieben R</b> . Nouveaux aspects immunologiques et cliniques des groupes sanguins ABO. <i>Médecine et Hygiène</i> 1992;50:1334-1337.   |      |      |
| 2.  | Nydegger UE, <b>Rieben R</b> , Aeschbacher B. Biocompatibility of apheresis harness. <i>Transfus Sci</i> 1990;11(1):43-54.   | 1.30 | 0.17 |
| 1.  | Nydegger UE, <b>Rieben R</b> , Jungi TW. Synergy between plasma exchange and intravenous immunoglobulin. In: Nydegger UE, ed. <i>Therapeutic Hemapheresis in the 1990's</i> . Basel: Karger, 1990: 31-50. (Hässig A, Lundsgaard-Hansen P, eds. <i>Current Studies in Hematology and Blood Transfusion</i> ; Vol 57). | —    | —    |